Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10669295 | 0.80 | CYSLTR1 (0.57) | TSHRCYSLTR1CYSLTR2SMN1; SMN2PDE10A | |
| SCHEMBL28119918 | 0.80 | TSHR (0.41) | TSHRCYP1A2HTR3AHRH4CYSLTR1 | |
| SCHEMBL30838793 | 0.79 | CYP1A2 (0.42) | CYP1A2HTR3AHRH4KDM4EGPR3 | |
| SCHEMBL1514912 | 0.79 | CYP1A2 (0.42) | CYP1A2HTR3AHRH4KDM4EGPR3 | |
| SCHEMBL28840069 | 0.77 | ALDH1A1 (0.38) | CYP1A2HTR3AHRH4CYSLTR1CYSLTR2 | |
| SCHEMBL27825404 | 0.76 | CYP1A2 (0.38) | TSHRCYP1A2HTR3AHRH4CYSLTR1 | |
| SCHEMBL9971271 | 0.76 | KDM4E (0.44) | CYP1A2HTR3AHRH4KDM4EGPR3 | |
| SCHEMBL716117 | 0.75 | TSHR (0.50) | TSHRCYP1A2HTR3AHRH4KDM4E | |
| SCHEMBL7168931 | 0.75 | SMN1; SMN2 (0.51) | CYSLTR1KDM4EEGFRSTAT3HTT | |
| SCHEMBL8112158 | 0.75 | PDE10A (0.47) | CYSLTR1CYSLTR2SMN1; SMN2PDE10AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | TSHR 3313/4885CYP1A2 3088/4885HTR3A 2704/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | TSHR 3313/4885CYP1A2 3088/4885HTR3A 2704/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | TSHR 3335/4885CYP1A2 2671/4885HTR3A 1873/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | TSHR 4727/4885CYP1A2 3456/4885HTR3A 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.